Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data
We conducted a review and meta-analysis to establish the international pooled prevalence of psychotropic drugs in children and adolescents, and comment on recent trends.
Medline, Embase, and PsycINFO were searched for studies with annual prevalence estimates of attention deficit hyperactivity disorder (ADHD) medications, antidepressants, antipsychotics, sedative/hypnotics and anxiolytics in outpatient children and adolescents. Data were extracted regarding the representativeness, sampling frame, and the quality of reporting.
A total of 59 studies reporting prevalence data for 23 countries were collected. Most studies were conducted in Europe (42) and were at high or moderate risk of bias (35).
The global random-effect pooled prevalence was 15.3‰ (95% confidence interval [CI], 7.6–25.7‰) for ADHD medications, 6.4‰ (95%CI 4.3–8.7) for antidepressants, and 5.5‰ (95%CI 3.6–7.8) for antipsychotics. Heterogeneity was extremely high (I2 > 99%). Large increases were found in the prevalence of ADHD medications in most countries, particularly up until 2010. The antidepressants’ trend was U-shaped in most countries with the lowest prevalence in 2007–2009 and rise more recently. Large to weak increases in the prevalence of antipsychotics were seen until 2011, and contrasting data were found more recently. Data on anxiolytics and sedative/hypnotics were limited.
The study provides global estimates of paediatric psychotropic drug prevalence and its trends. Systematic monitoring is lacking in most countries, and very heterogeneous reporting is common across studies.
KeywordsChild Adolescent Prevalence Psychotropic drugs Prescriptions Outpatients
The authors would like to acknowledge Judith Baggott for language editing.
Authors’ individual contributions
All the authors contributed equally to the design of the study. DP and AC reviewed the studies. DP wrote the first draft of the manuscript. AC contributed to writing the manuscript. MB supervised the study. All authors contributed to and have approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ (2017) International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur Neuropsychopharmacol 27(10):1064–1076. https://doi.org/10.1016/j.euroneuro.2017.07.001 Google Scholar
- 7.Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A, European Child and Adolescent Clinical Psychopharmacology Network (2015) Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol 25(10):1513–1531. https://doi.org/10.1016/j.euroneuro.2015.06.009 Google Scholar
- 9.Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65(9):934–939. https://doi.org/10.1016/j.jclinepi.2011.11.014 Google Scholar
- 10.DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188Google Scholar
- 13.Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CCM, Hoffmann F, Aagaard L, Zito JM (2017) Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol 27(5):484–493. https://doi.org/10.1016/j.euroneuro.2017.03.002 Google Scholar
- 18.Furu K, Karlstad Ø, Zoega H, Martikainen JE, Bahmanyar S, Kieler H, Pottegård A (2017) Utilization of stimulants and atomoxetine for attention-deficit/hyperactivity disorder among 5.4 million children using population-based longitudinal data. Basic Clin Pharmacol Toxicol 120(4):373–379. https://doi.org/10.1111/bcpt.12724 Google Scholar
- 23.Librero J, Izquierdo-María R, García-Gil M, Peiró S (2015) Children’s relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain. Med Clin (Barc) 145(11):471–476. https://doi.org/10.1016/j.medcli.2015.02.022 Google Scholar
- 26.Morkem R, Patten S, Queenan J, Barber D (2017) Recent trends in the prescribing of ADHD medications in Canadian primary care. J Atten Disord:1087054717720719. https://doi.org/10.1177/1087054717720719
- 27.Nyarko KA, Grosse SD, Danielson ML, Holbrook JR, Visser SN, Shapira SK (2017) Treated prevalence of attention-deficit/hyperactivity disorder increased from 2009 to 2015 among school-aged children and adolescents in the United States. J Child Adolesc Psychopharmacol 27(8):731–734. https://doi.org/10.1089/cap.2016.0196 Google Scholar
- 30.Schubert I, Köster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German state of Hesse, 2000-2007. Dtsch Arztebl Int 107(36):615–621. https://doi.org/10.3238/arztebl.2010.0615 Google Scholar
- 37.Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, Petersen I, Schuiling-Veninga CC, Wijlaars L, Zito JM, Hoffmann F (2016) Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacol 26(3):411–419. https://doi.org/10.1016/j.euroneuro.2016.02.001 Google Scholar
- 40.Clavenna A, Andretta M, Pilati P, Dusi M, Gangemi M, Gattoni MB, Lombardo G, Zoccante L, Mezzalira L, Bonati M (2011) Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatr 11(40). https://doi.org/10.1186/1471-2431-11-40
- 52.Volkers AC, Heerdink ER, van Dijk L (2007) Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 16(9):1054–1062Google Scholar
- 58.Kalverdijk LJ, Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Hoffmann F, Petersen I, Schuiling-Veninga CCM, Wijlaars LP, Zito JM (2017) A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child Adolesc Psychiatry Ment Health 11(55):55. https://doi.org/10.1186/s13034-017-0192-1 Google Scholar
- 62.Ronsley R, Scott D, Warburton WP, Hamdi RD, Louie DC, Davidson J, Panagiotopoulos C (2013) A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatr 58(6):361–369. https://doi.org/10.1177/070674371305800608 Google Scholar
- 65.Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A (2016) Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. Eur J Clin Pharmacol 72(7):869–876. https://doi.org/10.1007/s00228-016-2044-y Google Scholar
- 68.John A, Marchant AL, McGregor JI, Tan JO, Hutchings HA, Kovess V, Choppin S, Macleod J, Dennis MS, Lloyd K (2015) Recent trends in the incidence of anxiety and prescription of anxiolytics and hypnotics in children and young people: an e-cohort study. J Affect Disord 183:134–141. https://doi.org/10.1016/j.jad.2015.05.002 Google Scholar
- 69.O’Sullivan K, Reulbach U, Boland F, Motterlini N, Kelly D, Bennett K, Fahey T (2015) Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland. BMJ Open 5(6):e007070. https://doi.org/10.1136/bmjopen-2014-007070 Google Scholar
- 71.Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP, Termine C, Bonati M, Lombardy ADHD Group (2017) Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry 26(12):1443–1457. https://doi.org/10.1007/s00787-017-1005-z Google Scholar
- 79.Hilverdink P, Daamen W, Vink C (2015) Children and youth support and care in the Netherlands. Neth Youth Inst (www.nji.nl/english); Rapport (8). http://www.youthpolicy.nl/en/Download-NJi/Publicatie-NJi/Children-and-youth-support-and-care-in-The-Netherlands.pdf
- 82.World Health Organization and Calouste Gulbenkian Foundation (2014) Social determinants of mental health. World Health Organization, GenevaGoogle Scholar